Loading stock data…
SMTI
$22.72+0.63 (+2.85%)
Market ClosedLast close Jun 9
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sanara MedTech Inc. in the Healthcare sector is trading at $22.72. Wall Street consensus targets $34.00 (2 analysts), implying a +49.6% move over the next 12 months. The stock is currently 37% below its 52-week high of $35.95, remaining 5.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +49.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$22.72
Potential Downside
0%
Whystock Fair Value$22.72
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolys...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-477.72%
Volume
Today's trading volume
80,471
Recent News
Sanara MedTech (SMTI) Q1 2026 Earnings Transcript
Seth Yon: Thank you, operator, and welcome, everyone, to our first quarter 2026 earnings conference call. Demand for our products is strong, and we're particularly pleased with our first quarter results given that our first quarter is historically our seasonally slowest sales period of the year. Despite these challenges, we closed out the first quarter with the strongest sales month in company history in March, excluding October of 2024, which benefited from approximately $1.8 million of BIASURGE sales due to the industry disruption caused by Hurricane Helene.
How The Sanara MedTech (SMTI) Narrative Is Shifting As The US$34 Target Stays Put
Sanara MedTech’s fair value target is held at US$34.00 per share, with no change from the previous US$34.00 estimate. Bullish and bearish analysts are reading that steady target very differently, with some seeing it as a sign of conviction in the updated model and others viewing it as heavily dependent on specific assumptions. As you read on, you will see what is driving these views and how to track the narrative as it develops. Analyst Price Targets don't always capture the full story. Head...
Sanara MedTech Inc. Q1 2026 Earnings Call Summary
Moby summary of Sanara MedTech Inc.'s Q1 2026 earnings call
Sanara MedTech Inc (SMTI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Sanara MedTech Inc (SMTI) reports a 19% revenue increase and strategic sales team expansion, despite facing operational challenges.
ICU Medical (ICUI) Tops Q1 Earnings and Revenue Estimates
ICU Medical (ICUI) delivered earnings and revenue surprises of +10.67% and +1.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?